Underdog Pharmaceuticals logo
Startup

Underdog Pharmaceuticals

See Underdog Pharmaceuticals's full profile

BOOK A DEMO
Headquarters

United States

Founded Year

2019

Total Funding

$4.0M

Employees

11 - 50

Status

Active


About Underdog Pharmaceuticals

The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration.

Headquarters

United States


General Information on Underdog Pharmaceuticals

Brand name Underdog Pharmaceuticals
Company name Underdog Pharmaceuticals Inc.
Website https://underdogpharma.com/
Founded year 2019
Employees 11 - 50
Contact [email protected]

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about Underdog Pharmaceuticals

GoingPublic Online 28.09.2021
Underdog Pharmaceuticals erhält Finanzierung über 10 Mio. USD

WerbungDas US-Biotech-Unternehmen Underdog Pharmaceuticals, ein Portfoliounternehmen des Karlsruher Biotech-Investors Kizoo, hat eine Kapitalrunde von 10 Mio. USD abgeschlossen. Kizoo leitete die Series Seed-II-Runde des Unternehmens, an der sowohl bestehende als auch neue Investoren teilnahmen.Underdog: Kohlenhydratverbindung UDP-003 bekämpft toxisches oxidiertes CholesterinMit bis zu 40% der Todesfälle in Europa und den USA sind ...

Swissquote (Switzerland) (German) 23.09.2021
BRIEF-Kizoo Portfolio Co Underdog Pharmaceuticals Closes $10 Mln Financing Round

Sept 23- Underdog Pharmaceuticals Inc:* KIZOO PORTFOLIO COMPANY UNDERDOG CLOSES $10 M FINANCING ROUNDSource text for Eikon:

Menafn.com 08.09.2021
Underdog Pharmaceuticals Awarded 'Innovation Passport'by UK Regulators

stage pharmaceutical company focusing on the treatment and reversal of age-related diseases, has been awarded an Innovation Passport under the United Kingdom's Innovative Licensing and Access Pathway (ILAP), to pursue fast patient access to its groundbreaking treatment for cardiovascular disease.Accounting for more than 40% of deaths in Europe and the United States, and with annual treatment costs more than £29 billion in the UK alone, ...